06.09.2023 • NewsCorden PharmaPeptidesinvestment

CordenPharma Completes Upgrade of US Peptide Production Site in Colorado

CDMO CordenPharma, a specialist in active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, inaugurated an increased commercial peptide production capacity with newly-upgraded facilities at its Colorado site in the US, which the company says is the world's largest solid-phase peptide synthesis (SPPS) manufacturing facility.

The inauguration follows the signature of a multi-year large scale peptide manufacturing agreement earlier this year.

Since the approval of investments in early 2023, CordenPharma said that it completed a series of upgrades and modernizations to the facility which have increased the efficiency and throughput of SPPS peptide production, allowing for increased capacity to service current and future customers across a growing pharmaceutical innovator base.

The implemented measures included upgrades to the existing 10,000 l reactor volume with a batch size exceeding 400 kg and a yearly capacity of more than 2 metric tons of peptide; a 50% increase in downstream HPLC purification capacity; automation upgrades; the implementation of PAT for amino acid identification and ready-to-use process intensification with continuous washing and reaction monitoring; and the modernization of critical infrastructure for increased efficiency of solvent delivery (> 150’000 L) and effluent removal.

The company expects to increase the existing workforce of currently 500 employees by a further 60.

CordenPharma CEO Michael Quirmbach and CordenPharma Colorado managing director...
CordenPharma CEO Michael Quirmbach and CordenPharma Colorado managing director Brian McCudden at the inauguration of the increased peptide production at the company's newly updated large-scale manufacturing facility in Colorado on Aug. 22, 2023. The picutures also show a modernized tank farm (on the left) and a filter dryer for crude peptide isolation (on the right). Source: CordenPharma

“This expansion marks another milestone for CordenPharma, cementing our position as the leading large-scale peptide CDMO partner to the pharmaceutical and biotech industry,” commented CordenPharma’s CEO Michael Quirmbach.

Stéphane Varray, CordenPharma’s global peptide platform director, added: “CordenPharma is pleased to celebrate the start of peptide production in our newly upgraded and expanded SPPS manufacturing facility in Colorado with the largest worldwide peptide capacity available. These modernizations will allow for increased efficiency, throughput, and access to state-of-the-art technologies for streamlined commercial peptide API supply.”

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.